MannKind Corporation (NASDAQ:MNKD) has risen sharply, recording gains of 15.84% in the past 4 weeks. However, the stock has corrected -0.85% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 14% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The company shares have dropped -78.99% from its 1 Year high price. On Jul 16, 2015, the shares registered one year high at $5.80 and the one year low was seen on Jan 6, 2016. The 50-Day Moving Average price is $1.07 and the 200 Day Moving Average price is recorded at $1.21.
The stock has recorded a 20-day Moving Average of 5.5% and the 50-Day Moving Average is 6.12%.
MannKind Corporation (NASDAQ:MNKD): stock turned positive on Friday. Though the stock opened at $1.14, the bulls momentum made the stock top out at $1.17 level for the day. The stock recorded a low of $1.12 and closed the trading day at $1.17, in the green by 2.63%. The total traded volume for the day was 2,286,428. The stock had closed at $1.14 in the previous days trading.
In an insider trading activity, Castagna Michael, officer (Chief Commercial Officer) of Mannkind Corp, executed a transaction worth $46,500 on May 17, 2016. A total of 50,000 shares were purchased at an average price of $0.93. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.